<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9861593
   </pmid>
   <datecreated>
    <year>
     1999
    </year>
    <month>
     03
    </month>
    <day>
     03
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1999
    </year>
    <month>
     03
    </month>
    <day>
     03
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1059-7115
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       7
      </volume>
      <issue>
       9
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Nov
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research
     </title>
     <isoabbreviation>
      J Womens Health
     </isoabbreviation>
    </journal>
    <articletitle>
     Magnesium supplementation alleviates premenstrual symptoms of fluid retention.
    </articletitle>
    <pagination>
     <medlinepgn>
      1157-65
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      We investigated the effect of a daily supplement of 200 mg of magnesium (as MgO) for two menstrual cycles on the severity of premenstrual symptoms in a randomized, double-blind, placebo-controlled, crossover study. A daily supplement of 200 mg of Mg (as MgO) or placebo was administered for two menstrual cycles to each volunteer, who kept a daily record of her symptoms, using a 4-point scale in a menstrual diary of 22 items. Symptoms were grouped into six categories: PMS-A (anxiety), PMS-C (craving), PMS-D (depression), PMS-H (hydration), PMS-O (other), and PMS-T (total overall symptoms). Urinary Mg output/24 hours was estimated from spot samples using the Mg/creatinine ratio. Analysis of variance for 38 women showed no effect of Mg supplementation compared with placebo in any category in the first month of supplementation. In the second month there was a greater reduction (p = 0.009) of symptoms of PMS-H (weight gain, swelling of extremities, breast tenderness, abdominal bloating) with Mg supplementation compared with placebo. Compliance to supplementation was confirmed by the greater mean estimated 24-hour urinary output of Mg (p = 0.013) during Mg supplementation (100.8 mg) compared with placebo (74.1 mg). A daily supplement of 200 mg of Mg (as MgO) reduced mild premenstrual symptoms of fluid retention in the second cycle of administration.
     </abstracttext>
    </abstract>
    <affiliation>
     Hugh Sinclair Unit of Human Nutrition, Department of Food Science and Technology, University of Reading, U.K.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Walker
      </lastname>
      <forename>
       A F
      </forename>
      <initials>
       AF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       De Souza
      </lastname>
      <forename>
       M C
      </forename>
      <initials>
       MC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vickers
      </lastname>
      <forename>
       M F
      </forename>
      <initials>
       MF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Abeyasekera
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Collins
      </lastname>
      <forename>
       M L
      </forename>
      <initials>
       ML
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Trinca
      </lastname>
      <forename>
       L A
      </forename>
      <initials>
       LA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Womens Health
    </medlineta>
    <nlmuniqueid>
     9208978
    </nlmuniqueid>
    <issnlinking>
     1059-7115
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      1309-48-4
     </registrynumber>
     <nameofsubstance>
      Magnesium Oxide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7439-95-4
     </registrynumber>
     <nameofsubstance>
      Magnesium
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cross-Over Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Monitoring
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Magnesium
     </descriptorname>
     <qualifiername majortopicyn="N">
      urine
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Magnesium Oxide
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Premenstrual Syndrome
     </descriptorname>
     <qualifiername majortopicyn="Y">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Questionnaires
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Severity of Illness Index
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Water-Electrolyte Imbalance
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      urine
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9861593
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

